T2 Biosystems Past Earnings Performance
Past criteria checks 0/6
T2 Biosystems's earnings have been declining at an average annual rate of -0.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 12.1% per year.
Key information
-0.4%
Earnings growth rate
58.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 12.1% |
Return on equity | n/a |
Net Margin | -696.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price
Apr 18T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease
Oct 13T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M
Sep 29T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement
Sep 22T2 Biosystems' Survival Riddle
Aug 26T2 Biosystems Q2 2022 Earnings Preview
Aug 12T2 Biosystems drops 4% on Q2 guidance and 2022 outlook
Jul 06A Roadmap To T2 Biosystems Story
Mar 08T2 Biosystems (NASDAQ:TTOO) Has Debt But No Earnings; Should You Worry?
Aug 17Revenue & Expenses BreakdownBeta
How T2 Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7 | -50 | 25 | 0 |
30 Sep 23 | 11 | -50 | 26 | 0 |
30 Jun 23 | 13 | -52 | 27 | -6 |
31 Mar 23 | 17 | -64 | 29 | 0 |
31 Dec 22 | 22 | -62 | 31 | 0 |
30 Sep 22 | 24 | -64 | 31 | -1 |
30 Jun 22 | 28 | -61 | 32 | 14 |
31 Mar 22 | 28 | -55 | 32 | 0 |
31 Dec 21 | 28 | -49 | 29 | 0 |
30 Sep 21 | 29 | -47 | 27 | 1 |
30 Jun 21 | 27 | -44 | 24 | 0 |
31 Mar 21 | 23 | -43 | 21 | 0 |
31 Dec 20 | 18 | -47 | 22 | 0 |
30 Sep 20 | 13 | -51 | 24 | 0 |
30 Jun 20 | 10 | -54 | 25 | 0 |
31 Mar 20 | 9 | -59 | 27 | 0 |
31 Dec 19 | 8 | -59 | 27 | 0 |
30 Sep 19 | 7 | -60 | 26 | 0 |
30 Jun 19 | 8 | -57 | 26 | 0 |
31 Mar 19 | 10 | -53 | 27 | 0 |
31 Dec 18 | 11 | -51 | 26 | 0 |
30 Sep 18 | 10 | -54 | 25 | 0 |
30 Jun 18 | 9 | -58 | 24 | 0 |
31 Mar 18 | 6 | -61 | 23 | 0 |
31 Dec 17 | 5 | -62 | 23 | 0 |
30 Sep 17 | 4 | -59 | 23 | 0 |
30 Jun 17 | 4 | -57 | 23 | 0 |
31 Mar 17 | 4 | -56 | 24 | 0 |
31 Dec 16 | 4 | -55 | 24 | 0 |
30 Sep 16 | 4 | -52 | 23 | 0 |
30 Jun 16 | 4 | -51 | 23 | 0 |
31 Mar 16 | 4 | -48 | 21 | 0 |
31 Dec 15 | 3 | -45 | 19 | 0 |
30 Sep 15 | 2 | -42 | 18 | 0 |
30 Jun 15 | 1 | -40 | 16 | 0 |
31 Mar 15 | 0 | -38 | 14 | 0 |
31 Dec 14 | 0 | -36 | 11 | 0 |
30 Sep 14 | 0 | -35 | 9 | 0 |
30 Jun 14 | 0 | -33 | 7 | 0 |
31 Mar 14 | 0 | -31 | 6 | 0 |
31 Dec 13 | 0 | -28 | 5 | 0 |
Quality Earnings: TTOO is currently unprofitable.
Growing Profit Margin: TTOO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TTOO is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.
Accelerating Growth: Unable to compare TTOO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TTOO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TTOO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.